SAM
CPRX

Shamrock Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Shamrock Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200
Closed -$1K – 250
2014
Q2 		$1K Buy
+200
New +$427 ﹤0.01% 272

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Shamrock Asset Management's CPRX Position: Q3 2014 in Review

Shamrock Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2014, closing a stake of 200 shares — an estimated $1K sold.

Shamrock Asset Management first reported a position in CPRX in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 52 funds tracked by Wall St. Rank hold CPRX as of Q3 2014.

  • Shamrock Asset Management reported no remaining Catalyst Pharmaceutical position as of Q3 2014 after selling out during the quarter.
  • Shamrock Asset Management sold 200 Catalyst Pharmaceutical shares in Q3 2014, an estimated $1K.
  • Shamrock Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 1 quarter.
  • Shamrock Asset Management's Catalyst Pharmaceutical position peaked at $1K in Q2 2014.
  • 52 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2014.

Based on Shamrock Asset Management's 13F filing for Q3 2014, filed 29 Oct 2014.